Physician profile
Carrie B Wallace
NPI 1659646768
$11,892.27
in general payments reported to CMS, 2019-2025
45 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,506 · 2022: $2,354 · 2023: $2,861 · 2024: $2,665 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,020 · Education: $12.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,019.57 |
| Education | $12.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,799.34 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $990.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $978.94 | 2021-2025 | Afrezza |
| Abbott Laboratories | $881.14 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $814.17 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $672.79 | 2021-2025 | Repatha, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $556.96 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $533.80 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $510.96 | 2021-2025 | Omnipod |
| Corcept Therapeutics | $467.95 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $459.84 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $416.42 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.69 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $266.28 | 2021-2022 | |
| Medtronic, INC. | $199.50 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $192.34 | 2024-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.69 | 2022-2023 | Cycloset |
| Cequr Corporation | $143.92 | 2024-2025 | Cequr Simplicity |
| Pfizer INC. | $127.00 | 2022-2024 | |
| Ibsa Pharma INC. | $123.81 | 2021-2025 | Tirosint, Licart, Flector |
| Amneal Pharmaceuticals LLC | $110.88 | 2021-2024 | Unithroid |
| Kyowa Kirin, INC. | $101.80 | 2022-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $96.73 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $91.02 | 2022-2025 | Strensiq |
| Beta Bionics, INC. | $88.34 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Zealand Pharma US, INC. | $83.63 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $76.16 | 2023 | |
| Ascendis Pharma Endocrinology INC | $73.29 | 2025 | Yorvipath |
| Abbvie INC. | $65.97 | 2021-2024 | |
| Amphastar Pharmaceuticals, INC. | $64.65 | 2023-2025 | Baqsimi |
| Sequel Med Tech, LLC | $63.98 | 2025 | Twiist |
| Astellas Pharma US INC | $58.86 | 2023-2024 | Veozah |
| Genentech USA, INC. | $49.16 | 2023-2024 | Phesgo, Perjeta, Kadcyla |
| Amryt Pharma Holdings LTD | $48.03 | 2023 | Mycapssa |
| Celgene Corporation | $36.06 | 2021 | |
| Lifescan, INC. | $34.71 | 2021-2022 | |
| Esperion Therapeutics, INC. | $30.92 | 2021 | |
| Madrigal Pharmaceuticals | $29.74 | 2025 | Rezdiffra |
| Bigfoot Biomedical INC | $22.27 | 2022 | |
| Chiesi USA, INC. | $21.36 | 2025 | Mycapssa |
| Horizon Therapeutics Plc | $21.34 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $20.14 | 2025 | Imcivree |
| Clarus Therapeutics INC. | $16.78 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2021 | |
| Antares Pharma, INC. | $12.97 | 2023 | Xyosted, Nocdurna, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.